Revenue grew 54.9% year over year to $242.7M in 2026Q3 and gross margin held near 98.6%, but a -53.8% operating margin and a -45.3% net margin show that R&D intensity has kept profitability out of reach.
Ionis Pharmaceuticals, Inc. (IONS) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Sales/Revenue | 959.76M | 944M | 705.14M | 787.65M | 587.37M | 810.46M | 729.26M | 1.12B | 599.67M | 514.18M | 372.78M | 283.7M | 214.16M | 147.28M | 102.05M | 99.09M | 108.47M | 121.6M | 107.19M | 58.34M | 14.86M | 40.13M | 42.62M | 49.99M | 80.18M | 53.27M | 37.26M | 33.9M | 39.2M | 32.7M | 22.7M |
| Revenue Growth % | -0.74% | 33.87% | -10.48% | 34.1% | -27.53% | 11.13% | -35.04% | 87.2% | 16.63% | 37.93% | 31.4% | 32.47% | 45.41% | 44.33% | 2.99% | -8.65% | -10.8% | 13.44% | 83.72% | 292.65% | -62.98% | -5.84% | -14.73% | -37.65% | 50.51% | 43% | 9.9% | -13.52% | 19.88% | 44.05% | 74.62% |
| Cost of Goods Sold | 17.04M | 16M | 11.21M | 9.13M | 14.12M | 10.84M | 11.95M | 4.38M | 1.82M | 0 | 0 | 322.29M | 241.75M | 184.03M | 158.46M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -5.54M | -5.2M | -4.3M | -3.2M | -2.6M |
| COGS % of Revenue | - | 1.69% | 1.59% | 1.16% | 2.4% | 1.34% | 1.64% | 0.39% | 0.3% | - | - | 113.6% | 112.88% | 124.95% | 155.28% | - | - | - | - | - | - | - | - | - | - | - | -14.86% | -15.34% | -10.97% | -9.79% | -11.45% |
| Gross Profit | 942.72M | 928M | 693.92M | 778.51M | 573.25M | 799.61M | 717.32M | 1.12B | 597.85M | 514.18M | 372.78M | -38.59M | -27.59M | -36.75M | -56.41M | 99.09M | 108.47M | 121.6M | 107.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 42.79M | 39.1M | 43.5M | 35.9M | 25.3M |
| Gross Margin % | 98.22% | 98.31% | 98.41% | 98.84% | 97.6% | 98.66% | 98.36% | 99.61% | 99.7% | 100% | 100% | -13.6% | -12.88% | -24.95% | -55.28% | 100% | 100% | 100% | 100% | - | - | - | - | - | - | - | 114.86% | 115.34% | 110.97% | 109.79% | 111.45% |
| Gross Profit Growth % | - | 33.73% | -10.87% | 35.81% | -28.31% | 11.47% | -35.85% | 87.04% | 16.27% | 37.93% | 1066.02% | -39.87% | 24.92% | 34.85% | -156.93% | -8.65% | -10.8% | 13.44% | - | - | - | - | - | - | - | -100% | 9.44% | -10.11% | 21.17% | 41.9% | 60.13% |
| Operating Expenses | 1.51B | 1.31B | 1.17B | 1.13B | 983.44M | 829.8M | 889.4M | 752.33M | 659.23M | 483.13M | 392.94M | 37.17M | 20.14M | 14.92M | 12.52M | 170.19M | 156.83M | 149.14M | 120.25M | 91.26M | 80.08M | 97.31M | 160.48M | 128.97M | 130.99M | 99.38M | 71.78M | 82.2M | 76M | 67.2M | 54.4M |
| OpEx % of Revenue | - | 138.77% | 165.78% | 143.75% | 167.43% | 102.39% | 121.96% | 67.02% | 109.93% | 93.96% | 105.41% | 13.1% | 9.4% | 10.13% | 12.26% | 171.76% | 144.58% | 122.65% | 112.18% | 156.42% | 538.91% | 242.48% | 376.49% | 257.99% | 163.37% | 186.54% | 192.67% | 242.48% | 193.88% | 205.5% | 239.65% |
| Selling, General & Admin | 584.98M | 394M | 267.5M | 232.6M | 150.29M | 170.9M | 332.2M | 286.64M | 244.62M | 108.49M | 48.62M | 37.17M | 20.14M | 14.92M | 12.52M | 12.79M | 11.67M | 14.52M | 13.81M | 13.06M | 11.2M | 7.89M | 9.58M | 10.2M | 5.54M | 15.63M | 9.23M | 10.6M | 9.5M | 8.1M | 51.8M |
| SG&A % of Revenue | - | 41.74% | 37.94% | 29.53% | 25.59% | 21.09% | 45.55% | 25.53% | 40.79% | 21.1% | 13.04% | 13.1% | 9.4% | 10.13% | 12.26% | 12.91% | 10.76% | 11.94% | 12.88% | 22.38% | 75.39% | 19.65% | 22.47% | 20.41% | 6.92% | 29.35% | 24.78% | 31.27% | 24.23% | 24.77% | 228.19% |
| Research & Development | 923.16M | 916M | 901.53M | 899.63M | 833M | 643M | 535M | 466M | 414.6M | 374.64M | 344.32M | 322.29M | 241.75M | 184.03M | 158.46M | 157.4M | 145.16M | 134.62M | 106.44M | 92.64M | 80.57M | 82.47M | 118.47M | 116.96M | 124.07M | 83.74M | 57.01M | 66.4M | 62.2M | 55.9M | 45.7M |
| R&D % of Revenue | - | 97.03% | 127.85% | 114.22% | 141.82% | 79.34% | 73.36% | 41.51% | 69.14% | 72.86% | 92.37% | 113.6% | 112.88% | 124.95% | 155.28% | 158.85% | 133.82% | 110.71% | 99.3% | 158.78% | 542.21% | 205.48% | 277.95% | 233.97% | 154.75% | 157.19% | 153.04% | 195.87% | 158.67% | 170.95% | 201.32% |
| Other Operating Expenses | 0 | 0 | -26K | 19K | 147K | 15.9M | 22.2M | -312K | 0 | 0 | 0 | -322.29M | -241.75M | -184.03M | -158.46M | 0 | 0 | 0 | 0 | 0 | -536K | 6.96M | 32.43M | 1.8M | 1.37M | 0 | 5.54M | 5.2M | 4.3M | 3.2M | -43.1M |
| Operating Income | -565.42M | -382M | -475.08M | -353.73M | -410.19M | -30.19M | -172.08M | 365.88M | -61.37M | 31.05M | -20.16M | -75.76M | -47.73M | -51.67M | -68.92M | -71.1M | -48.36M | -27.54M | -13.06M | -32.92M | -65.22M | -57.18M | -117.85M | -78.98M | -50.81M | -46.1M | -28.99M | -43.1M | -32.5M | -31.3M | -29.1M |
| Operating Margin % | -58.91% | -40.47% | -67.37% | -44.91% | -69.84% | -3.72% | -23.6% | 32.59% | -10.23% | 6.04% | -5.41% | -26.7% | -22.29% | -35.08% | -67.54% | -71.76% | -44.58% | -22.65% | -12.18% | -56.42% | -438.91% | -142.48% | -276.49% | -157.99% | -63.37% | -86.54% | -77.82% | -127.14% | -82.91% | -95.72% | -128.19% |
| Operating Income Growth % | - | 19.59% | -34.31% | 13.76% | -1258.88% | 82.46% | -147.03% | 696.17% | -297.67% | 254% | 73.39% | -58.73% | 7.62% | 25.04% | 3.06% | -47.03% | -75.6% | -110.86% | 60.33% | 49.52% | -14.05% | 51.48% | -49.22% | -55.43% | -10.22% | -59.03% | 32.74% | -32.62% | -3.83% | -7.56% | -13.67% |
| EBITDA | -543.52M | -359.31M | -453.09M | -331.23M | -388.09M | -10.63M | -154.92M | 381.88M | -48.84M | 39.4M | -11.13M | -65.52M | -38.33M | -41.88M | -58.17M | -59.32M | -39.18M | -18.23M | -6.24M | -26.15M | -58M | -46.8M | -105.68M | -66.72M | -41.39M | -39.13M | -23.45M | -37.9M | -28.2M | -28.1M | -26.5M |
| EBITDA Margin % | -56.63% | -38.06% | -64.26% | -42.05% | -66.07% | -1.31% | -21.24% | 34.02% | -8.15% | 7.66% | -2.98% | -23.1% | -17.9% | -28.44% | -57% | -59.86% | -36.12% | -15% | -5.82% | -44.83% | -390.35% | -116.6% | -247.94% | -133.48% | -51.62% | -73.46% | -62.96% | -111.8% | -71.94% | -85.93% | -116.74% |
| EBITDA Growth % | -111.14% | 20.7% | -36.79% | 14.65% | -3552.23% | 93.14% | -140.57% | 881.83% | -223.98% | 454.06% | 83.02% | -70.96% | 8.49% | 28% | 1.93% | -51.4% | -114.86% | -192.09% | 76.13% | 54.91% | -23.94% | 55.72% | -58.39% | -61.21% | -5.76% | -66.85% | 38.11% | -34.4% | -0.36% | -6.04% | -16.23% |
| D&A (Non-Cash Add-back) | 21.89M | 22.69M | 21.99M | 22.5M | 22.11M | 19.56M | 17.16M | 15.99M | 12.53M | 8.35M | 9.03M | 10.24M | 9.4M | 9.78M | 10.76M | 11.78M | 9.18M | 9.3M | 6.82M | 6.76M | 7.22M | 10.38M | 12.17M | 12.25M | 9.42M | 6.97M | 5.54M | 5.2M | 4.3M | 3.2M | 2.6M |
| EBIT | -495.43M | -307M | -375.71M | -258.37M | -249.86M | -24.75M | -128.35M | 351.21M | -31.37M | 27.99M | -18.67M | -51.17M | -32.18M | -47.2M | -53.44M | -68.06M | -47.93M | -19.09M | -2.71M | -32.92M | -65.75M | -50.22M | -85.43M | -77.17M | -49.44M | -46.1M | -28.99M | -43.1M | -32.5M | -31.3M | -29.1M |
| Net Interest Income | 13.92M | 7.22M | 16.57M | 7.58M | 17.21M | 695K | 21.05M | 3.44M | -14.6M | -36.57M | -33.38M | -32.43M | -19.53M | -17.27M | -19.31M | -14.32M | -9.86M | -6.31M | 5.71M | 3.87M | -3.07M | -15.22M | -19.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 89.99M | 97.77M | 107.02M | 89.04M | 25.33M | 10.04M | 30.56M | 52.2M | 30.19M | 8.18M | 5.42M | 4.3M | 2.68M | 2.08M | 1.84M | 2.41M | 3.37M | 6.36M | 11.32M | 11.44M | 5.96M | 5.09M | 3M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 76.07M | 90.54M | 90.45M | 81.46M | 8.12M | 9.35M | 9.51M | 48.77M | 44.79M | 44.75M | 38.8M | 36.73M | 22.21M | 19.36M | 21.15M | 16.73M | 13.23M | 12.67M | 5.6M | 7.57M | 9.03M | 20.31M | 22.59M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 21.61M | 2M | 15.01M | 19.77M | 152.21M | 1.04M | 37.53M | -27.12M | -14.78M | -47.81M | -37.31M | -12.14M | -6.66M | -14.89M | -5.66M | -13.69M | -12.8M | -4.23M | -1.46M | 32.92M | 65.22M | 57.18M | 117.85M | 78.98M | 50.81M | 46.1M | 28.99M | 43.1M | 32.5M | 31.3M | 29.1M |
| Pretax Income | -543.8M | -380M | -460.07M | -333.96M | -257.99M | -29.15M | -134.55M | 338.77M | -76.16M | -16.76M | -57.47M | -87.91M | -54.39M | -66.56M | -74.59M | -84.79M | -61.16M | -31.77M | -14.52M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pretax Margin % | -56.66% | -40.25% | -65.25% | -42.4% | -43.92% | -3.6% | -18.45% | 30.18% | -12.7% | -3.26% | -15.42% | -30.99% | -25.4% | -45.19% | -73.09% | -85.57% | -56.38% | -26.12% | -13.55% | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | -187K | 1M | -6.17M | 32.32M | 11.74M | -551K | 345.19M | 51.51M | -291.14M | -5.98M | 2.93M | 372K | -15.41M | -5.91M | -9.11M | 11K | 92K | 3.19M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.03% | -0.26% | 1.34% | -9.68% | -4.55% | 1.89% | -256.55% | 15.2% | 382.3% | 35.67% | -5.11% | -0.42% | 28.33% | 8.89% | 12.21% | -0.01% | -0.15% | -10.05% | 0% | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -546.14M | -381M | -453.9M | -366.29M | -269.72M | -28.6M | -444.26M | 278.14M | 273.74M | 346K | -60.4M | -88.28M | -38.98M | -60.64M | -65.48M | -84.8M | -61.25M | 155.07M | -18.17M | -10.99M | -45.9M | -72.4M | -142.5M | -95M | -72.24M | -73.83M | -53.48M | -59.2M | -43M | -31.1M | -26.5M |
| Net Margin % | -56.9% | -40.36% | -64.37% | -46.5% | -45.92% | -3.53% | -60.92% | 24.78% | 45.65% | 0.07% | -16.2% | -31.12% | -18.2% | -41.17% | -64.16% | -85.58% | -56.47% | 127.52% | -16.95% | -18.84% | -308.92% | -180.4% | -334.33% | -190.03% | -90.1% | -138.59% | -143.56% | -174.63% | -109.69% | -95.11% | -116.74% |
| Net Income Growth % | -113.05% | 16.06% | -23.92% | -35.8% | -843.18% | 93.56% | -259.72% | 1.61% | 79015.9% | 100.57% | 31.58% | -126.45% | 35.72% | 7.38% | 22.79% | -38.45% | -139.5% | 953.32% | -65.29% | 76.05% | 36.6% | 49.19% | -50.01% | -31.5% | 2.15% | -38.04% | 9.65% | -37.67% | -38.26% | -17.36% | -11.81% |
| Net Income (Continuing) | -543.62M | -381M | -453.9M | -366.29M | -269.72M | -28.6M | -479.74M | 287.26M | 214.99M | -10.78M | -60.4M | -88.28M | -38.98M | -60.64M | -65.48M | -84.8M | -61.25M | -34.96M | -14.52M | -4.96M | -43M | -72.4M | -142.5M | -95M | -72.24M | -73.83M | -53.48M | -59.2M | -43M | -31.1M | -26.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 185.63M | -8.39M | -6.03M | -2.9M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 213.45M | 139.08M | 84.27M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10.34M | 37.16M | 9.37M | 29.34M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.29 | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 | 2.06 | 2.04 | 0.15 | -0.72 | -0.74 | -0.33 | -0.55 | -0.65 | -0.85 | -0.62 | 1.58 | -0.13 | -0.13 | -0.62 | -1.15 | -2.52 | -1.71 | -1.33 | -1.67 | -1.44 | -2.06 | -1.60 | -1.17 | -1.04 |
| EPS Growth % | -94.15% | 21.71% | -18.75% | -34.74% | -850% | 93.71% | -254.37% | 0.98% | 1260% | 120.83% | 2.7% | -124.24% | 40% | 15.38% | 23.53% | -37.1% | -139.24% | 1315.38% | 0% | 79.03% | 46.09% | 54.37% | -47.37% | -28.57% | 20.36% | -15.97% | 30.1% | -28.75% | -36.75% | -12.5% | 5.45% |
| EPS (Basic) | - | -2.38 | -3.04 | -2.56 | -1.90 | -0.20 | -3.18 | 2.10 | 2.07 | 0.15 | -0.72 | -0.74 | -0.33 | -0.55 | -0.65 | -0.85 | -0.62 | 1.58 | -0.13 | -0.13 | -0.62 | -1.15 | -2.52 | -1.71 | -1.33 | -1.67 | -1.44 | -2.06 | -1.60 | -1.17 | -1.04 |
| Diluted Shares Outstanding | 166.21M | 160M | 149.51M | 143.19M | 141.85M | 141.02M | 139.61M | 142.87M | 134.06M | 126.1M | 120.93M | 119.72M | 117.69M | 110.5M | 100.58M | 99.66M | 99.14M | 98.11M | 94.57M | 83.74M | 74.31M | 62.88M | 56.64M | 55.46M | 54.48M | 44.11M | 37.02M | 28.7M | 26.87M | 26.58M | 25.48M |
| Basic Shares Outstanding | 166.21M | 160M | 149.51M | 143M | 141.85M | 141.02M | 139.61M | 140M | 132.32M | 124.02M | 120.8M | 119.29M | 117.69M | 110.5M | 100.58M | 99.66M | 99.14M | 98.11M | 94.57M | 83.74M | 74.31M | 62.88M | 56.64M | 55.46M | 54.48M | 44.11M | 37.02M | 28.7M | 26.87M | 26.58M | 25.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying IONS stock.
For fiscal year 2025, Ionis Pharmaceuticals, Inc. (IONS) reported total revenue of $944.0M. This represents a 4058.6% increase compared to $22.7M in 1996.
Ionis Pharmaceuticals, Inc. (IONS) reported a net loss of $381.0M for the fiscal year ending 2025.
Ionis Pharmaceuticals, Inc. (IONS) reported an operating income of $-382.0M, resulting in an operating profit margin of -40.5%. This margin reflects the operational efficiency of the business before interest and taxes.
Ionis Pharmaceuticals, Inc. (IONS) generated $928.0M in gross profit for the year, representing a gross profit margin of 98.3%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Launch uptake execution shortfall
Metrics are mathematically derived from official filings.
Lumpy Revenue Masks Underlying Momentum
As reported in the quarterly income statements, Ionis posted revenue of $242.7M in 2026Q3, up 54.9% year over year, yet the series swings from $452.0M in 2025Q2 to $131.6M in 2025Q1, indicating milestone-driven rather than recurring revenue.
The swing pattern suggests top-line results are dominated by collaboration milestones and upfront recognition rather than a steadily compounding royalty or product base. Reading the 54.9% growth rate in isolation may overstate durability, since the comparison base includes the unusually large 2025Q2 quarter. Investors should monitor whether ex-milestone revenue begins to grow sequentially, which would indicate genuine commercial traction.
High Gross Margin Reflects Licensing Model
Based on reported figures, gross margin held between 96.1% and 99.2% across the ten quarters, with 2026Q3 at 98.6%, a level that reflects the absence of manufacturing-heavy cost of goods rather than operating efficiency.
Such a consistently high gross margin is characteristic of royalty and license income, which carries minimal direct cost, and it should not be read as evidence of pricing power in product manufacturing. The margin profile is likely to compress once self-commercialized products add COGS and distribution costs. Investors should watch for that transition as a structural change in the margin baseline.
Operating Losses Persist Despite Revenue Gains
According to the reported statements, R&D expense of $215.9M in 2026Q3 and SG&A of $154.2M produced an operating loss of $130.7M, a -53.8% operating margin that has not converged toward breakeven across the period.
Operating expenses are scaling roughly in step with revenue rather than lagging it, which indicates negative operating leverage at current revenue levels. The combined R&D and SG&A burden appears to be rising as the company builds a commercial organization. Without a sustained step-up in revenue, the operating cost base appears unlikely to be absorbed in the near term.
Stock Compensation Weighs on Reported Losses
Based on reported figures, stock-based compensation of $43.4M in 2026Q3 equals roughly 18% of the $242.7M revenue base, a meaningful non-cash component embedded within the $110.0M net loss.
A stock compensation charge of this size inflates the reported operating loss relative to cash burn, which is a relevant distinction when assessing funding needs. The 2025Q4 quarter shows no reported SBC, which warrants caution when comparing periods because the data is incomplete. Investors should reconcile net loss against operating cash flow before drawing conclusions about the underlying cost trajectory.
R&D Intensity Anchors the Cost Base
As reported in the quarterly data, R&D expense ran between $200.8M and $280.0M per quarter over the period, consistently exceeding total revenue in most quarters and making R&D the dominant cost driver of the business.
The persistence of R&D at this scale implies that pipeline investment is the primary determinant of operating results rather than commercial activity. Such intensity is typical of a platform company funding late-stage trials, though it leaves little margin for error if pipeline timelines slip. Management's ability to moderate R&D while adding sales capacity will be a key test of expense discipline.
Launch Uptake Could Lag Commercial Assumptions
Based on the supplied commentary, management described TRYNGOLZA's initial sales progress as more gradual than anticipated, a signal that could challenge the revenue ramp assumed by the self-commercialization thesis.
If prescriber adoption and payer access remain slower than planned, the fixed cost of a newly built sales force could deepen operating losses well beyond current levels. Debt-to-equity of 5.35 and return on equity of -70.7% suggest limited balance sheet tolerance for an extended ramp. Investors should treat the commercial transition as unproven until quarterly product revenue demonstrates sustained, non-milestone growth.